Merck HCV Combo Looks Even Better With Results In Patients Co-Infected With HIV

Data released at the Conference on Retroviruses and Opportunistic Infections show therapeutic effect post-treatment, but Merck has not yet obtained sustained virologic response data in the Phase II study. The data on genotype 1a patients and hard-to-cure HCV subpopulations will inform the design and goals of the Phase III program.